Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: Retrospective analysis in a Nagano Lung Cancer Research Group Study

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Tateishi, Kazunari ^a   Ichiyama, Takashi ^a   Hirai, Kazuya ^b   Agatsuma, Toshihiko ^c   Koyama, Shigeru ^d   Hachiya, Tsutomu ^e   Morozumi, Nobutoshi ^f   Shiina, Takayuki ^a   Koizumi, Tomonobu ^g  

^a SHINSHU UNIVERSITY   (Japan)

^b Nagano Municipal Hospital   (Japan)

^c Shinshu Ueda Medical Center   (Japan)

^d NAGANO RED CROSS HOSPITAL   (Japan)

^e Suwa Red Cross Hospital   (Japan)

^f Nagano Prefectural Federation of Agricultural Cooperative for Health and Welfare   (Japan)

^g SHINSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

EGFR mutations; Elderly patients; First line; Gefitinib; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PEMETREXED; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ARTICLE; CANCER CONTROL; CANCER GROWTH; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GENE; AGED; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; LUNG TUMOR; MORTALITY; MUTATION; PROTO ONCOGENE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENES, ERBB-1; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84880639764     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0450-2     Document Type: Article

References (25)

1. Matsuda T, Marugame T, Kamo K, et al. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2012;42:139-47.
2. Marugame T, Matsuda T. Comparison of time trends in lung cancer incidence (1973-2002) in Asia, from cancer incidence in five continents Vols IV-IX. Jpn J Clin Oncol. 2009;39:133-5.
3. Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med. 1993;14:453-78.
4. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570-7.
5. Azzoli CG, Baker S Jr, Temin S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol. 2009;27:6251-66.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8.
7. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of eastern cooperative oncology group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:173-81.
8. Provencio M, Camps C, Alberola V, et al. Lung cancer and treatment in elderly patients: the Achilles study. Lung Cancer. 2009;66:103-6.
9. The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 1999;91:66-72.
10. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan thoracic oncology group trial (WJTOG 9904). J Clin Oncol. 2006;24:3657-63.
11. Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493-8.
12. Inoue A, Kobayashi K, Usui K, et al. North East Japan gefitinib study group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 2009;27:1394-400.
13. Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122-8.
14. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-8.
15. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121-8.
16. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.
17. Asami K, Koizumi T, Hirai K, Ameshima S, et al. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer. 2011;12:387-92.
18. Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7:1417-22.
19. Travis WD, Colby TV, Corrin B et al. Histological typing of lung and pleural tumors. World Health Organization international histological classification of tumors. 3rd ed. Berlin: Springer; 1999.
20. Travis WD, Brambilla E, Muller-Hermelink HK et al. Pathology and genetics. Tumors of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004.
21. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposalsfor the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706-14.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
23. Title of subordinate document. In: Common terminology criteria for adverse events (CTCAE) Version 4.0. National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-40 of subordinate document (2012). Accessed 28 Nov 2012.
24. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362-72.
25. Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan study group 002 trial. Oncologist. 2012;17:863-70.